Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 3, 2011, Pages 635-640

  Jackson, Akil ^a   Hill, Andrew ^b   Puls, Rebekah ^c   Else, Laura ^b   Amin, Janaki ^c   Back, David ^b   Lin, Enmoore ^c   Khoo, Saye ^b   Emery, Sean ^c   Morley, Roland ^a   Gazzard, Brian ^a   Boffito, Marta ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antiretroviral therapy; HIV antiviral pharmacology; Pharmacokinetics

Indexed keywords

LOPINAVIR PLUS RITONAVIR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS; MALE; NORMAL HUMAN; PHARMACOLOGICAL PARAMETERS; STEADY STATE; TABLET;

ADMINISTRATION, ORAL; ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMAN EXPERIMENTATION; HUMANS; MALE; MIDDLE AGED; PLASMA; PYRIMIDINONES; RITONAVIR;

EID: 79951527317     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq468     Document Type: Article

References (13)

1. Klein CE, Chiu Y-L, Awni W et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr 2007; 44: 401-10.
2. Murphy RL, Brun S, Hicks C et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001; 15: F1-9.
3. Gazzard BG on behalf of the BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563-608.
4. Boffito M, Else L, Back D et al. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. Antivir Ther 2008; 13: 901-7.
5. Hill A, van der Lugt J, Sawyer W et al. How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials. AIDS 2009; 23: 2237-45.
6. Else L, Watson V, Tjia J et al. Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 1455-65.
7. González de Requena D, Blanco F, Garcia-Benayas T et al. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir. AIDS Patient Care STDS 2003; 17: 443-5.
8. Gutiérrez F, Padilla S, Navarro A et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens. J Acquir Immune Defic Syndr 2003; 33: 594-600.
9. Dickinson L, Khoo S, Back D. Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Curr Opin HIV AIDS 2008; 3: 296-305.
10. van der Lugt J, Autar RS, Ubolyam S et al. Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults. J Antimicrob Chemother 2008; 61: 1145-53.
11. La Porte CJ, Back DJ, Blaschke T et al. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev Antivir Ther 2006; 3: 3-14.
12. Ananworanich J, Kosalaraksa P, Hill A et al. Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children. Pediatr Infect Dis J 2005; 24: 874-9.
13. Wateba MI, Billaud E, Dailly E et al. Low initial trough plasma concentrations of lopinavir are associated with an impairment of virological response in an unselected cohort of HIV-1-infected patients. HIV Med 2006; 7: 197-9.